Two large phase-3 trials of Novavax's COVID-19 vaccine show high levels of protection against infection: Research head

SII and Novavax are the key partners in the development and manufacturing of the Novavax vaccine, marketed by Novavax as Nuvaxovid and by SII as Covovax, from its facility in Pune.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/g9XAEqS
via IFTTT